John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
USX
2126
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $372K | ﹤0.01% |
+95,776
| New | +$429K |
|
2127
MINISO
MNSO
$3.36B
| $371K | ﹤0.01% |
47,510
-78,130
| -62% | -$719K |
|
|
WNS
2128
DELISTED
WNS Holdings
WNS
| $369K | ﹤0.01% |
4,319
-26,775
| -86% | -$2.29M |
|
|
AXNX
2129
DELISTED
Axonics, Inc. Common Stock
AXNX
| $369K | ﹤0.01% |
5,899
-40,495
| -87% | -$2.18M |
|
2130
Savara
SVRA
$1.15B
| $368K | ﹤0.01% |
280,785
-322,983
| -53% | -$389K |
|
2131
Bank of N.T. Butterfield & Son
NTB
$2.29B
| $365K | ﹤0.01% |
+10,159
| New | +$385K |
|
2132
Clarus
CLAR
$145M
| $364K | ﹤0.01% |
15,980
+8,690
| +119% | +$201K |
|
2133
Inogen
INGN
$147M
| $364K | ﹤0.01% |
11,220
-4,604
| -29% | -$145K |
|
|
AXDX
2134
DELISTED
Accelerate Diagnostics
AXDX
| $362K | ﹤0.01% |
25,169
-4,485
| -15% | -$128K |
|
2135
Churchill Downs
CHDN
$6.18B
| $361K | ﹤0.01% |
3,252
-2,454
| -43% | -$270K |
|
2136
Nexa Resources
NEXA
$2.1B
| $360K | ﹤0.01% |
38,502
+26,874
| +231% | +$233K |
|
|
CONN
2137
DELISTED
Conn's Inc.
CONN
| $360K | ﹤0.01% |
+23,378
| New | +$504K |
|
|
NAGE
2138
Niagen Bioscience
NAGE
$259M
| $358K | ﹤0.01% |
145,690
-41,721
| -22% | -$114K |
|
|
OSG
2139
DELISTED
Overseas Shipholding Group Inc.
OSG
| $358K | ﹤0.01% |
+171,365
| New | +$333K |
|
2140
Nkarta
NKTX
$194M
| $357K | ﹤0.01% |
31,402
-97,879
| -76% | -$1.05M |
|
2141
Arbutus Biopharma
ABUS
$1.03B
| $355K | ﹤0.01% |
119,081
-766,456
| -87% | -$2.35M |
|
|
TBHC
2142
DELISTED
The Brand House Collective
TBHC
| $355K | ﹤0.01% |
+38,198
| New | +$544K |
|
|
CMLS
2143
DELISTED
Cumulus Media Inc. Class A Common Stock
CMLS
| $355K | ﹤0.01% |
35,704
+2,755
| +8% | +$29.3K |
|
2144
Mega Matrix
MPU
$14.7M
| $354K | ﹤0.01% |
+177,166
| New | +$1M |
|
|
EVLO
2145
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $352K | ﹤0.01% |
5,196
+4,529
| +679% | +$377K |
|
|
CWBR
2146
DELISTED
CohBar, Inc. Common Stock
CWBR
| $349K | ﹤0.01% |
37,041
-5,370
| -13% | -$50.8K |
|
|
SII
2147
Sprott
SII
$3.54B
| $346K | ﹤0.01% |
6,889
-55,655
| -89% | -$2.31M |
|
|
BRDG
2148
DELISTED
Bridge Investment Group
BRDG
| $345K | ﹤0.01% |
16,937
-44,430
| -72% | -$930K |
|
2149
Forte Biosciences
FBRX
$1.63B
| $345K | ﹤0.01% |
9,456
-2,344
| -20% | -$88.7K |
|
2150
Vital Farms
VITL
$477M
| $345K | ﹤0.01% |
+27,927
| New | +$419K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.